Impax to divest 10 products amid acquisition by Amneal

The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic

1 April 2019 Pharmaceutical company Impax Laboratories engaged in illegal pay-for-delay settlements to stop a generic version of one of its medications from entering the market, the US Federal Trade Commission has ruled.

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Impax to divest 10 products amid acquisition by Amneal

More on this story

Editor's picks

Editor's picks

More features